Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) stock closed at 1.01 per share at the end of the most recent trading day (a 4.21% change compared to the prior day closing price) with a volume of 332.92K shares and market capitalization of 44.60M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 29 people. Eiger BioPharmaceuticals Inc. CEO is David Cory.

The one-year performance of Eiger BioPharmaceuticals Inc. stock is -89.8%, while year-to-date (YTD) performance is -14.41%. EIGR stock has a five-year performance of -90%. Its 52-week range is between 0.95 and 10.0213, which gives EIGR stock a 52-week price range ratio of 0.66%

Eiger BioPharmaceuticals Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.68, a price-to-sale (PS) ratio of 4.82, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -71.15%, a ROC of -76.31% and a ROE of -121.23%. The company’s profit margin is -35.57%, its EBITDA margin is -627.10%, and its revenue ttm is $10.79 Million , which makes it $0.24 revenue per share.

Of the last four earnings reports from Eiger BioPharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Eiger BioPharmaceuticals Inc.’s next earnings report date is 04th May 2023.

The consensus rating of Wall Street analysts for Eiger BioPharmaceuticals Inc. is Strong Buy (1), with a target price of $9.2, which is +810.89% compared to the current price. The earnings rating for Eiger BioPharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eiger BioPharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eiger BioPharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.62, ATR14 : 0.13, CCI20 : -89.70, Chaikin Money Flow : -0.34, MACD : -0.23, Money Flow Index : 29.18, ROC : -34.42, RSI : 27.06, STOCH (14,3) : 7.69, STOCH RSI : 0.69, UO : 32.26, Williams %R : -92.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eiger BioPharmaceuticals Inc. in the last 12-months were: Christine Murray (Sold 5 000 shares of value $6 104 ), David Apelian (Sold 5 000 shares of value $49 031 ), Eldon C. Mayer (Sold 4 395 shares of value $4 704 ), Jeffrey S Glenn (Buy at a value of $127 950), Thomas J. Dietz (Buy at a value of $71 580), Thomas J. Dietz (Sold 22 500 shares of value $26 303 )